Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
Launched by HOSPITAL CLINIC OF BARCELONA · Apr 11, 2012
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Potentially sexual exposition to HIV
- Exclusion Criteria:
- • Pregnancy
- • Source case with antiretroviral resistances
- • any treatment contraindicated with the drugs of study
About Hospital Clinic Of Barcelona
The Hospital Clinic of Barcelona is a leading academic medical center renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry to enhance patient outcomes. As a prominent sponsor of clinical trials, the Hospital Clinic of Barcelona is dedicated to exploring new therapies and treatment modalities across various medical fields, fostering a culture of excellence in clinical research that ultimately aims to improve the quality of care for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
Felipe Garcia, PhD
Principal Investigator
Consultant senior
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials